other material
confidence high
sentiment positive
materiality 0.90
Definium Therapeutics reports positive Phase 3 results for DT120 ODT in major depressive disorder
Definium Therapeutics, Inc.
- Study met primary endpoint with 8.1-point MADRS placebo-adjusted improvement at Week 6 (p<0.0001)
- 7.3-point MADRS placebo-adjusted improvement at Week 12 (p<0.0001), showing durability
- DT120 ODT was generally well tolerated; no serious adverse events or suicidality signal
- Company to host webcast at 8:00 a.m. EDT on June 22, 2026 to discuss results